Selected Controversies of Radioiodine Imaging and Therapy in Differentiated Thyroid Cancer.

Douglas Van Nostrand

Journal: Endocrinology and metabolism clinics of North America 2018;46(3):783-793

PMID: 28760238

Full Text on Elsevier Science View on PubMed

Abstract

This article discusses the more controversial areas of the management of differentiated thyroid cancer, namely, the utility of pretherapy staging radioiodine scans; the prescribed activity for iodine-131 remnant ablation, adjuvant treatment, and distant metastases; preparation with thyroid hormone withdrawal versus recombinant human thyroid-stimulating hormone; and the classification of radioiodine refractory differentiated thyroid cancer. The author reviews various aspects of the controversies, such as the recommendations of the 2015 guidelines of the American Thyroid Association, arguments for and against the various controversies, and selected references.

Address: Nuclear Medicine Research, Division of Nuclear Medicine, MedStar Health Research Institute, MedStar Washington Hospital Center, Georgetown University School of Medicine, Suite GA60F, 110 Irving Street, Northwest, Washington, DC 20010, USA. Electronic address: [email protected].

DOI: 10.1016/j.ecl.2017.04.007

Link outs

Free resources

Medical:

https://medlineplus.gov/thyroidcancer.html

Other Literature Sources:

https://scite.ai/reports/28760238

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Iodine Radioisotopes, Thyroid Hormones, Thyroid Neoplasms, Thyrotropin